Compare Cassava Sciences Inc (FLNA) vs United Parcel Service Inc (UPS) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

UPS trades at $113.67, up 0.69% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. Revenue has moderated from $100.3B in 2022 to $88.7B in 2025, but profitability remains solid with a 5.94% net margin and strong ROE of 33.41%. The company is investing in healthcare logistics and AI to boost efficiency, with Q2 2026 earnings due July 28.

The outlook is mixed: valuation is reasonable (P/E 18.28), but revenue headwinds and Amazon's logistics expansion pose risks. Analyst consensus is neutral with a $112 price target, slightly below the current price. Dividend sustainability is a focus amid competitive pressures, though cost controls support cash flow.